GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Total Receivables

CERO (CERo Therapeutics Holdings) Total Receivables : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Total Receivables?

CERo Therapeutics Holdings's Total Receivables for the quarter that ended in Sep. 2024 was $0.00 Mil.


CERo Therapeutics Holdings Total Receivables Historical Data

The historical data trend for CERo Therapeutics Holdings's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Total Receivables Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Total Receivables
- -

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Total Receivables Get a 7-Day Free Trial Premium Member Only - - 0.16 0.09 -

CERo Therapeutics Holdings Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


CERo Therapeutics Holdings Total Receivables Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, South San Francisco, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.